AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3882356
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic at all (control group)
Trial: 31899170
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose behavioral coaching (16 sessions over 24 months)
Trial: 31899170
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose behavioral coaching (32 sessions over 24 months)
Trial: 31899170
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose behavioral coaching (48 sessions over 24 months)
Trial: 25448092
Drug: AS03‐adjuvanted A/turkey/Turkey/1/05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03‐adjuvanted A/turkey/Turkey/1/05 H5N1 vaccine (3.75 or 7.5 μg HA)
Trial: 25448092
Drug: AS03A‐adjuvanted booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03A‐adjuvanted booster vaccine (3.75 μg HA)
Trial: 23271615
Drug: Whole apples
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole apples (550 g/day)
Trial: 23271615
Drug: Apple pomace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple pomace (22 g/day)
Trial: 23271615
Drug: Cloudy apple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cloudy apple juice (500 ml/day)
Trial: 23271615
Drug: Clear apple
RxNorm normalized name: Ensure Clear Apple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear apple juice (500 ml/day)
Trial: 9357934
Drug: 120-min infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120-min infusion of 10 cal/oz formula
Trial: 9357934
Drug: 120-min infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120-min infusion of 20 cal/oz formula
Trial: 9357934
Drug: Water and
RxNorm normalized name: ALCOHOL 71 mL in 100 mL TOPICAL GEL [Anti Bacterial Hand Gel Rose Water and Ivy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water and half-strength formula as slow infusion
Trial: 9357934
Drug: Full-strength formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-strength formula as slow infusion
Trial: 1605959
Drug: Steroids +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids + acyclovir (intravenous doses for Ramsay Hunt's syndrome)
Trial: 1605959
Drug: Steroids (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids (control group for Bell's palsy)
Trial: 1605959
Drug: Acyclovir (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (oral doses for Bell's palsy)
Trial: 8773063
Drug: Paracetamol 10
RxNorm normalized name: Paracetamol 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 10 mg/kg
Trial: 4072592
Drug: Aminophenazone 4
RxNorm normalized name: Aminophenazon
DrugBank: Aminophenazone (DB01424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophenazone 4 mg/kg and Diazepam 0.2 mg/kg
Trial: 29359279
Drug: High-dose baclofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose baclofen
Trial: 22705951
Drug: Ultrasound-guided ilioinguinal
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided ilioinguinal and iliohypogastric nerve block with 20 mL bupivacaine 0.5%
Trial: 22705951
Drug: Placebo block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo block with 20 mL saline
Trial: 8403274
Drug: Diethylcarbamazine (DEC)
RxNorm normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine (DEC) (6 mg/kg)
Trial: 12011121
Drug: Aza C
RxNorm normalized name: BAZA CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aza C (75 mg/m² subcutaneous for 7 days every 4 weeks)
Trial: 10745332
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin G (IVIG) 1 g/kg on three consecutive days
Trial: 7874928
Drug: Metered-dose inhaler
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered-dose inhaler (MDI) - 400 micrograms of albuterol
Trial: 7874928
Drug: Rotahaler -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotahaler - 400 micrograms of albuterol
Trial: 7874928
Drug: Diskhaler -
RxNorm normalized name: zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Diskhaler - 400 micrograms of albuterol
Trial: 2211570
Drug: Buspirone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (mean dose 41-54 mg/day from Week 2 to end of study)
Trial: 30831541
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg melatonin (2 capsules of 5 mg each) once a day 1 hour before bedtime for 12 weeks
Trial: 27864672
Drug: Rhinolight® intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhinolight® intranasal phototherapy (combination of UV‐B, UV‐A, and high‐intensity visible light)
Trial: 27864672
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (low‐intensity visible white light intranasal phototherapy)
Trial: 27864672
Drug: Rhinolight® intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhinolight® intranasal phototherapy
Trial: 23083020
Drug: Quetiapine 400
RxNorm normalized name: quetiapine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 400 mg/day
Trial: 20881844
Drug: Quetiapine 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 800 mg/day
Trial: 19930006
Drug: liraglutide 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 1.2 mg/metformin
Trial: 19930006
Drug: liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 1.8 mg/metformin
Trial: 19930006
Drug: liraglutide (monotherapy)
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: liraglutide (monotherapy)
Trial: 19930006
Drug: glimepiride/metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glimepiride/metformin
Trial: 16426800
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly functional-skills training
Trial: 16426800
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of resistance and functional-skills training
Trial: 12044130
Drug: Alternative medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative medicine therapies (specifics not provided)
Trial: 12044130
Drug: Placebo effect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo effect of unconventional medicine
Trial: 24311403
Drug: Hormonal replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal replacement therapy
Trial: 7892882
Drug: Dietary calcium
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary calcium augmentation
Trial: 2576217
Drug: Vecuronium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.2 mg/kg
Trial: 2576217
Drug: Vecuronium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.3 mg/kg
Trial: 2576217
Drug: Vecuronium 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.4 mg/kg
Trial: 795434
Drug: Diflucortolone valerate
RxNorm normalized name: diflucortolone valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflucortolone valerate (Nerisona) in cream, ointment, and fatty ointment
Trial: 795434
Drug: Diflucortolone valerate
RxNorm normalized name: diflucortolone valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflucortolone valerate (Nerisona) ointment
Trial: 795434
Drug: Commercial preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial preparations (beta‐methasone‐17‐valerate, fluocinonide, fluocinolone acetonide, flumetasone pivalate, desoximetasone)
Trial: 23549824
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at effect-site concentration of 4 ng/mL (group R4)
Trial: 23549824
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at effect-site concentration of 2 ng/mL (group R2)
Trial: 23549824
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at effect-site concentration of 6 ng/mL (group R6)
Trial: 19414206
Drug: 5.6 mmol/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.6 mmol/l cutoff for impaired fasting glucose
Trial: 19414206
Drug: 6.1 mmol/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.1 mmol/l cutoff for impaired fasting glucose
Trial: 16673249
Drug: Neoadjuvant TAC
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant TAC chemotherapy
Trial: 15220788
Drug: 12 ml/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 ml/h ropivacaine, 0.1% (group R)
Trial: 15220788
Drug: 12 ml/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 ml/h saline (group N)
Trial: 12941031
Drug: Oral heparin/SNAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral heparin/SNAC (90 000 U heparin)
Trial: 12941031
Drug: Oral heparin/SNAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral heparin/SNAC (60 000 U heparin)
Trial: 12941031
Drug: Subcutaneous UFH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous UFH (5000 U)
Trial: 10438403
Drug: Growth hormone-releasing
RxNorm normalized name: Growth hormone-releasing peptide 2
DrugBank: Pralmorelin (DB18252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Growth hormone-releasing factor (GRF) 500 microg twice daily
Trial: 7760609
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with busulphan or hydroxyurea (no IFN-alpha)
Trial: 2138703
Drug: hANP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hANP infusion (0.3 micrograms/min)
Trial: 6985706
Drug: Sulfinpyrazone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfinpyrazone (200 mg four times a day)
Trial: 26288467
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g single supervised dose of azithromycin
Trial: 26288467
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg azithromycin once daily for 5 days (conventional dose)
Trial: 16979581
Drug: Group-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based cognitive therapy (CT)
Trial: 16979581
Drug: Group-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based cognitive therapy (CT) and Psychoeducational support groups
Trial: 8182401
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and placebo tablets
Trial: 3885203
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg daily
Trial: 27529693
Drug: Play-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Play-based intervention (six clinic play-sessions, weekly home-modules, one-month home follow-up)
Trial: 24431325
Drug: Calcium-sensing receptor-activating
RxNorm normalized name: activated charcoal / calcium carbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-sensing receptor-activating amino acids (CaSR-AAAs) L-tryptophan, L-phenylalanine, and L-histidine
Trial: 24431325
Drug: Dibasic amino
RxNorm normalized name: Dibasic Potassium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dibasic amino acids (DAAs) L-arginine and L-lysine
Trial: 24431325
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (methylcellulose capsules)
Trial: 22622073
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (surgical exclusion of the internal carotid artery stump combined with endarterectomy of the external carotid artery)
Trial: 29950826
Drug: Glycopyrrolate/formoterol fumarate
RxNorm normalized name: glycopyrrolate/formoterol fumarate 9/4.8 MCG/INHAL Metered Dose Inhaler, 120 Actuations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 36/9.6 µg
Trial: 29950826
Drug: Glycopyrrolate/formoterol fumarate
RxNorm normalized name: glycopyrrolate/formoterol fumarate 9/4.8 MCG/INHAL Metered Dose Inhaler, 120 Actuations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 36/7.2 µg
Trial: 29950826
Drug: Glycopyrrolate/formoterol fumarate
RxNorm normalized name: glycopyrrolate/formoterol fumarate 9/4.8 MCG/INHAL Metered Dose Inhaler, 120 Actuations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 9/9.6 µg
Trial: 29950826
Drug: Glycopyrrolate (GP)
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (GP) MDI 36 µg
Trial: 29950826
Drug: Formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol fumarate (FF) MDI 9.6 µg
Trial: 26248047
Drug: Quinidine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (600 mg PO)
Trial: 26248047
Drug: Naloxegol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxegol (25 mg PO)
Trial: 26248047
Drug: Morphine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (5 mg/70 kg IV)
Trial: 26248047
Drug: Quinidine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine and naloxegol combination
Trial: 19606937
Drug: Amlodipine/valsartan combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan combination therapy
Trial: 17626056
Drug: Combined hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormone therapy (conjugated equine oestrogens plus medroxyprogesterone acetate 2.5/5.0 mg orally daily)
Trial: 17626056
Drug: Combined hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormone therapy
Trial: 16307967
Drug: 600 microg
RxNorm normalized name: Fentanyl 600 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 microg oral misoprostol (single-dose)
Trial: 16307967
Drug: 1200 microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 microg oral misoprostol (repeated-dose)
Trial: 9795070
Drug: New levodopa/benserazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New levodopa/benserazide dual-release formulation (DRF)
Trial: 9795070
Drug: Conventional slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional slow-release formulation (SRF)
Trial: 25915168
Drug: Aprepitant (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (375 mg once daily for 2 weeks)
Trial: 21407132
Drug: Nitrate supplementation
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate supplementation (NaNO(3) 10 mg·kg(‐1) of body mass)
Trial: 19585385
Drug: Intraprostatic injections
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAPROSTATIC LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraprostatic injections with mepivacaine epinephrine
Trial: 19585385
Drug: No intraprostatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intraprostatic injections
Trial: 17760598
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or 1:1 eutectic mixture of local anesthetics (EMLA) cream
Trial: 15220241
Drug: Pioglitazone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15 to 45 mg, titrated based on tolerability)
Trial: 9702847
Drug: Sustained-release tablet
RxNorm normalized name: Oratuss 12 Sustained-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release tablet of naproxen (500 mg once daily)
Trial: 9702847
Drug: Conventional tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional tablet of naproxen (250 mg twice daily)
Trial: 2478790
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg UD-CG 115 BS (pimobendan)
Trial: 2478790
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg UD-CG 115 BS (pimobendan)
Trial: 335788
Drug: Pizotifen (4-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pizotifen (4-10 mg daily)
Trial: 18624588
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) - Individual format (CBT-I)
Trial: 18624588
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) - Group format (CBT-G)
Trial: 18624588
Drug: Interpersonal Psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal Psychotherapy (IPT) - Group format (IPT-G)
Trial: 12665638
Drug: Extended letter
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended letter outlining treatment strategies based on subsequent central DXA scan results
Trial: 10560596
Drug: Celecoxib 50
RxNorm normalized name: celecoxib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 50 mg twice a day
Trial: 1879032
Drug: Therapeutic group
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic group (eleutherosides treatment)
Trial: 1879032
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (insulin and potassium chloride treatment)
Trial: 6461243
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of ferrous sulphate
Trial: 6461243
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg of ferrous sulphate
Trial: 6461243
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg of ferrous sulphate
Trial: 26603110
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of remifentanil (REM) at 0.05 μg/kg/min
Trial: 26603110
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of remifentanil (REM)
Trial: 22994060
Drug: Mesotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesotherapy with 2% procaine solution
Trial: 22994060
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% physiological solution)
Trial: 20200964
Drug: 800 IU
RxNorm normalized name: Vitamin E 800 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 IU of cholecalciferol and 1000 mg of calcium (calcium carbonate)
Trial: 18005834
Drug: Midpalatal implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midpalatal implant
Trial: 16223887
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of models I and II
Trial: 12297390
Drug: TA-CIN vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA-CIN vaccine (533 micro g dose)
Trial: 12297390
Drug: TA-CIN vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA-CIN vaccine (26, 128, 533 micro g doses)
Trial: 25200570
Drug: Dapagliflozin 2.5
RxNorm normalized name: dapagliflozin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 2.5 mg twice daily
Trial: 20302683
Drug: Olopatadine hydrochloride
RxNorm normalized name: Olopatadine Hydrochloride
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olopatadine hydrochloride nasal spray, 0.6% (OLO) + Fluticasone nasal spray, 50 micrograms (FNS)
Trial: 20302683
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray, 0.1% (AZE) + Fluticasone nasal spray, 50 micrograms (FNS)
Trial: 15602116
Drug: Sertraline with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline with cognitive behavioural therapy
Trial: 10537240
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and self-care education added to pharmaceutical treatment